DMACライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:25):

Stats
本日の出来高	7 284.00
平均出来高	39 550.00
時価総額	97.17M
EPS	$0 ( 2024-03-26 )
次の収益日	( $-0.160 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.27
ATR14	$0.0210 (0.82%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Lorianne Masuoka K.	Buy	285 000	Stock option (right to buy)
2024-01-22	Lorianne Masuoka K.	Buy	0
2024-01-02	Semba Charles Pauling	Buy	9 375	Voting Common Shares, no par value per share
2024-01-02	Kuntz Richard	Buy	14 285	Voting Common Shares, no par value per share
2024-01-02	Pilnik Richard D.	Buy	30 357	Voting Common Shares, no par value per share

INSIDER POWER
53.17
Last 91 transactions
Buy: 8 059 792 \| Sell: 2 870 847

DiaMedica Therapeutics 相関

10 最も正の相関
GSIT	0.944
APYX	0.943
EXAS	0.942
SPSC	0.94
MDB	0.939
PCYG	0.937
BSY	0.933
IESC	0.933
EWZS	0.931
SGH	0.929

10 最も負の相関
PAIC	-0.931
ONEM	-0.93
BLTE	-0.925
SVOK	-0.922
SOPA	-0.919
ONCR	-0.903
SVAC	-0.899
JRJC	-0.898
CIIG	-0.895
SBNYP	-0.888

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

DiaMedica Therapeutics 財務諸表

Annual	2023
収益:	$0
総利益:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2023
収益:	$0
総利益:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2022
収益:	$0
総利益:	$-25 000.00 (0.00 %)
EPS:	$-0.520

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.